133 related articles for article (PubMed ID: 38346600)
21. The Solubility-Permeability Interplay for Solubility-Enabling Oral Formulations.
Nainwal N; Singh R; Jawla S; Saharan VA
Curr Drug Targets; 2019; 20(14):1434-1446. PubMed ID: 31333138
[TBL] [Abstract][Full Text] [Related]
22. A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability.
Kim SJ; Lee HK; Na YG; Bang KH; Lee HJ; Wang M; Huh HW; Cho CW
Int J Pharm; 2019 Jan; 555():11-18. PubMed ID: 30448313
[TBL] [Abstract][Full Text] [Related]
23. Formulation of Dronedarone Hydrochloride-Loaded Proliposomes: In Vitro and In Vivo Evaluation Using Caco-2 and Rat Model.
Kovvasu SP; Kunamaneni P; Yeung S; Rueda J; Betageri GV
AAPS PharmSciTech; 2019 Jun; 20(6):226. PubMed ID: 31214813
[TBL] [Abstract][Full Text] [Related]
24. Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development.
Markovic M; Zur M; Fine-Shamir N; Haimov E; González-Álvarez I; Dahan A
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32214015
[TBL] [Abstract][Full Text] [Related]
25. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
[TBL] [Abstract][Full Text] [Related]
26. Toward Developing Discriminating Dissolution Methods for Formulations Containing Nanoparticulates in Solution: The Impact of Particle Drift and Drug Activity in Solution.
Arce FA; Setiawan N; Campbell HR; Lu X; Nethercott MJ; Bummer P; Su Y; Marsac PJ
Mol Pharm; 2020 Nov; 17(11):4125-4140. PubMed ID: 32965123
[TBL] [Abstract][Full Text] [Related]
27. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation.
Miller JM; Dahan A
Int J Pharm; 2012 Jul; 430(1-2):388-91. PubMed ID: 22465550
[TBL] [Abstract][Full Text] [Related]
28. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
30. Concomitant solubility-permeability increase: Vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide.
Beig A; Fine-Shamir N; Porat D; Lindley D; Miller JM; Dahan A
Eur J Pharm Biopharm; 2017 Dec; 121():97-103. PubMed ID: 28958946
[TBL] [Abstract][Full Text] [Related]
31. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
[TBL] [Abstract][Full Text] [Related]
32. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
[TBL] [Abstract][Full Text] [Related]
33. Dissolution/permeation with PermeaLoop™: Experience and IVIVC exemplified by dipyridamole enabling formulations.
Eriksen JB; Messerschmid R; Andersen ML; Wada K; Bauer-Brandl A; Brandl M
Eur J Pharm Sci; 2020 Nov; 154():105532. PubMed ID: 32871215
[TBL] [Abstract][Full Text] [Related]
34. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Miller JM; Beig A; Carr RA; Webster GK; Dahan A
Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
[TBL] [Abstract][Full Text] [Related]
35. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
[TBL] [Abstract][Full Text] [Related]
36. Predicting biopharmaceutical performance of oral drug candidates - Extending the volume to dissolve applied dose concept.
Muenster U; Mueck W; van der Mey D; Schlemmer KH; Greschat-Schade S; Haerter M; Pelzetter C; Pruemper C; Verlage J; Göller AH; Ohm A
Eur J Pharm Biopharm; 2016 May; 102():191-201. PubMed ID: 26955751
[TBL] [Abstract][Full Text] [Related]
37. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
Al-Ali AAA; Sandra L; Versweyveld D; Pijpers I; Dillen L; Vermeulen A; Snoeys J; Holm R; Nielsen CU
Int J Pharm; 2020 Jun; 583():119399. PubMed ID: 32376439
[TBL] [Abstract][Full Text] [Related]
38. Understanding
B Shekhawat P; B Pokharkar V
Acta Pharm Sin B; 2017 May; 7(3):260-280. PubMed ID: 28540164
[TBL] [Abstract][Full Text] [Related]
39. Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
Pade D; Jamei M; Turner DB; Mistry B; Martinez MN
Eur J Pharm Biopharm; 2019 Aug; 141():191-209. PubMed ID: 31150808
[TBL] [Abstract][Full Text] [Related]
40. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
